Jon Graham Anthony Steadman

Title: Jon Graham Anthony Steadman: Innovator in P2X7 Modulation

Introduction

Jon Graham Anthony Steadman is a notable inventor based in Harlow, GB. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate P2X7 receptor function. With a total of 2 patents, his work is aimed at addressing various medical conditions.

Latest Patents

Steadman's latest patents include innovative compounds such as 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives and 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives. These compounds are designed to modulate P2X7 receptor function and are believed to antagonize the effects of ATP at the P2X7 receptor. The applications of these inventions extend to the treatment and prophylaxis of inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis, and neurodegenerative disorders.

Career Highlights

Steadman is currently associated with Glaxo Group Limited, where he continues to advance his research and development efforts. His work has the potential to significantly impact the treatment of various pain-related and degenerative conditions.

Collaborations

Throughout his career, Steadman has collaborated with esteemed colleagues such as David Kenneth Dean and Jorge Munoz-Muriedas. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Jon Graham Anthony Steadman is a prominent figure in the field of pharmacology, with a focus on P2X7 modulation. His contributions through innovative patents are paving the way for new treatments in pain management and neurodegenerative disorders.